BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $89 from $90 and keeps a Buy rating on the shares. The firm slightly reduced 2026 expectations for Casgevy, but still expects continued sequential growth in 2026, the analyst tells investors in an earnings preview for the group.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- CRISPR Therapeutics Highlights Pipeline Advances in Gene-Edited Therapies
- Crispr Therapeutics highlights anticipated 2026 milestones
- Crispr Therapeutics says Casgevy exceeded $100M in revenue in 2025
- Crispr Therapeutics price target lowered to $90 from $93 at BofA
- Cathie Wood’s ARK Funds Had ‘One Heck of a Year’ — What’s Next for 2026?